文献速递免疫规划传染病防控与疫情报告

HIV感染暴露前预防人群中乙型肝炎疫苗基础免疫后的长期保护及加强剂应答

Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
PubMed 文献 · Vaccine · 2025-10-10

意大利米兰2017—2024年回顾性研究纳入447名35岁以下使用HIV暴露前预防的男男性行为者,PrEP启动时271人(60.6%)HBsAb≥10 mIU/mL,176人(39.4%)<10 mIU/mL;接受加强剂的55人中38人(69.1%)产生保护性HBsAb。作者建议对该高危人群系统筛查HBsAb并接种加强剂。

要点

  • PrEP启动时39.4%(176/447)的MSM缺乏保护性HBsAb。
  • 接受加强剂的55人中69.1%(38/55)产生保护性HBsAb。
  • 加强前HBsAb在2–9.9 mIU/mL者加强应答更好(p=0.032)。

核心结论

  • 近40%使用PrEP的MSM在基础HBV疫苗接种约30年后缺乏保护性HBsAb,约三分之一加强剂接种者未产生应答。
  • 作者建议对该高危人群系统筛查HBsAb并接种加强剂以确保充分保护。

研究设计与样本

  • 回顾性研究,纳入意大利米兰2017—2024年35岁以下使用PrEP的MSM,共447人。
  • PrEP启动时检测HBV血清学,HBsAb<10 mIU/mL者接受加强剂。

主要发现

  • 447名MSM中,271人(60.6%)HBsAb≥10 mIU/mL,176人(39.4%)<10 mIU/mL。
  • 保护性HBsAb在年龄较大者中更常见(p=0.014),在AST水平较高者中更常见(p=0.019)。
  • 176人中55人接受加强剂,其中38人(69.1%)产生保护性HBsAb。
  • 加强前HBsAb在2–9.9 mIU/mL与更好的加强应答相关(p=0.032)。

临床怎么用

  • 作者建议对使用PrEP的MSM系统筛查HBsAb并接种加强剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Universal hepatitis B virus (HBV) vaccination was introduced in Italy in 1991. However, the long-term durability of vaccine-induced protection remains under debate, particularly among high-risk groups such as men who have sex with men (MSM) using HIV pre-exposure prophylaxis (PrEP). This study aimed to assess HBV seroprotection and the immune response to a booster vaccine nearly 30 years after infant immunization among MSM-PrEP users. SETTING: This retrospective study included Italian MSM using PrEP under 35 years of age in Milan, Italy, between 2017 and 2024. METHODS: HBV serological status was determined at the start of PrEP. Participants with HBsAb levels below 10 mIU/mL were offered a booster dose. Statistical analyses were performed to compare demographic and clinical variables according to seroprotection status and booster response. RESULTS: Overall, among 447 MSM using PrEP, 271 (60.6 %) had HBsAb levels ≥10 mIU/mL, while 176 (39.4 %) <10 mIU/mL at the start of PrEP. Seroprotection was more prevalent among older participants (p = 0.014) and those with higher AST levels (p = 0.019). Of the 55/176 participants who received a booster, 38 (69.1 %) developed protective HBsAb levels. Pre-booster HBsAb levels between 2 and 9.9 mIU/mL were associated with a better booster response (p = 0.032). CONCLUSIONS: Almost 40 % of MSM using PrEP lacked protective HBsAb three decades after primary HBV vaccination, and around one-third of booster recipients failed to respond. Due to the high-risk nature of this group, systematic HBsAb screening and booster administration are recommended to ensure adequate protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Raccagni AR, Morsica G, Reali P, et al. Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection. Vaccine. 2025. PMID: 41075401. doi:10.1016/j.vaccine.2025.127825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。